The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: A pilot study

International Journal of Geriatric Psychiatry

Volumn 23, Issue 1, 2008, Pages 55-59

  Lavretsky, Helen ^a   Siddarth, Prabha ^a   Kumar, Anand ^a   Reynolds III, Charles F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Citalopram; Combined treatment; Dopamine transporter polymorphisms; Executive dysfunction; Geriatric depression; Methylphenidate; Psychostimulants; Serotonin transporter polymorphisms; Treatment response

Indexed keywords

CITALOPRAM; DOPAMINE TRANSPORTER; LORAZEPAM; METHYLPHENIDATE; SEROTONIN TRANSPORTER;

AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; GERONTOPSYCHIATRY; HAMILTON SCALE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR DEPRESSION; MALE; MONOTHERAPY; NAUSEA; OUTPATIENT; PHARMACOGENETICS; PILOT STUDY; POLYURIA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; VARIABLE NUMBER OF TANDEM REPEAT;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CENTRAL NERVOUS SYSTEM STIMULANTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PILOT PROJECTS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 38749119776     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1837     Document Type: Article

References (21)

1. Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. 2001. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol 11(6): 449-455.
2. Blier P, Bergeron R. 1997. Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments: are they related? Int Clin Psychopharmacol 12(Suppl 3): S21-S28.
3. Cook EH, Stein MA, Krasowski MD, et al. 1995. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56: 993-998.
4. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
5. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
6. Lavretsky H, Kumar A. 2001. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 9: 298-303.
7. Lavretsky H, Kim MD, Kumar A, Reynolds CF III 2003. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry 64(12): 1410-1414.
8. Lavretsky H, Park S, Siddarth P, et al. 2006. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 14(2): 181-185.
9. Lotrich FE, Pollock BG, Ferrell RE. 2001. Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogenomics 1(3): 153-164.
10. Lotrich FE, Pollock BG, Ferrell RE. 2003. Serotonin transporter promoter polymorphism in African Americans: allele frequencies and implications for treatment. Am J Pharmacogenomics 3(2): 145-147.
11. Millan MJ. 2004. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol 500(1-3): 371-384.
12. Mill J, Xu X, Ronald A, Curran S, et al. 2005. Quantitative trait locus analysis of candidate gene alleles associated with attention deficit hyperactivity disorder (ADHD) in five genes: DRD4, DATI, DRD5, SNAP-25, and 5HTI B. Am J Med Genet B Neuropsychiatr Genet 133(1): 68-73.
13. Neto PR. 2005. Activation of striatal dopamine receptors by psychostimulants: chemical anatomy, autonomic and behavioural effects. Dan Med Bull 52(3): 114.
14. Pollock BG, Ferrell RE, Mulsant BH, et al. 2000. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23(5): 587-590.
15. Reynolds CF III, Frank E, Dew MA, et al. 1999. Treatment of 70(+)-year-olds with recurrent major depression. Excellent short-term but brittle long-term response. Am J Geriatr Psychiatry 7: 64-69.
16. Reynolds CF III, Dew MA, Pollock BG, et al. 2006. Maintenance treatment of major depression in old age. N Engl J Med 354(11): 1130-1138.
17. Roman T, Szobot C, Martins S, et al. 2002. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 12: 497-499.
18. Smith GS, Lotrich FE, Malhotra AK, et al. 2004. Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology 29(12): 2226-2234.
19. Taylor WD, Steffens DC, Payne ME, et al. 2005. Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry 62(5): 537-544.
20. Trivedi MH, Rush AJ, Wisniewski SR, et al. and STAR*D Study Team. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163(1): 28-40.
21. Willner P. 1997. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 12 (Suppl 3): S7-S14.